CareDx, Inc. (CDNA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1151878,
    "name": "CareDx, Inc.",
    "stock_name": "CareDx, Inc.",
    "full_name": "CareDx, Inc.",
    "name_url": "stocks-analysis/caredx-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "19.41",
    "chg": 1.97,
    "chgp": "11.3%",
    "dir": 1,
    "prev_price": "17.44",
    "mcapval": "710.05",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US14167L1035",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.16 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/caredx-inc-1151878-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is CareDx, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-caredx-inc-overvalued-or-undervalued-3637643",
        "imagepath": "",
        "date": "2025-10-21 12:06:21",
        "description": "As of 17 October 2025, the valuation grade for CareDx, Inc. has moved from fair to very attractive, indicating a significant improvement in its perceived value. Based on the available metrics, CareDx appears to be undervalued, especially considering its Price to Book Value of 2.87 and an EV to Capital Employed ratio of 5.58, despite its negative earnings metrics. The company’s EV to Sales ratio stands at 2.49, which suggests a reasonable valuation relative to its sales, particularly when compared to peers like Organogenesis Holdings, Inc. with a P/E of 608.59 and Castle Biosciences, Inc. with an EV to EBITDA of -71.36.\n\nIn terms of stock performance, CareDx has faced substantial declines, with a year-to-date return of -32.70% compared to the S&P 500's 13.30%, and a five-year return of -72.05% against the S&P 500's 91.29%. This stark contrast reinforces the notion that CareDx may be undervalued, as its curre..."
      },
      {
        "title": "Is CareDx, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-caredx-inc-overvalued-or-undervalued-3634508",
        "imagepath": "",
        "date": "2025-10-20 12:23:41",
        "description": "As of 17 October 2025, the valuation grade for CareDx, Inc. moved from fair to very attractive, indicating a significant improvement in its valuation outlook. The company appears undervalued, particularly given its Price to Book Value of 2.87 and an EV to Sales ratio of 2.49, despite the negative P/E and ROE figures. CareDx's EV to EBIT stands at -27.94, which reflects its current loss-making status but also highlights potential for future recovery.\n\nIn comparison to its peers, CareDx's valuation metrics are notably more favorable, especially when contrasted with Organogenesis Holdings, Inc., which has a P/E ratio of 608.59, and Castle Biosciences, Inc., with an EV to EBITDA of -71.36. While CareDx has not provided multi-period return data, the overall market sentiment indicates a potential upside as it continues to navigate its challenges...."
      },
      {
        "title": "Is CareDx, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-caredx-inc-overvalued-or-undervalued-3632048",
        "imagepath": "",
        "date": "2025-10-19 12:01:14",
        "description": "As of 17 October 2025, CareDx, Inc. moved from fair to very attractive in valuation grade. The company appears undervalued given its current Price to Book Value of 2.87 and an EV to Capital Employed ratio of 5.58, despite being loss-making and having negative returns on capital and equity. In comparison to peers, CareDx's EV to EBITDA stands at -27.94, while Organogenesis Holdings, Inc. has a significantly higher P/E ratio of 608.59, indicating a stark contrast in valuation.\n\nNotably, CareDx's stock has underperformed against the S&P 500, with a year-to-date return of -32.70% compared to the index's 13.30%. This trend continues over longer periods, with a 5-year return of -72.05% versus the S&P 500's 91.29%, reinforcing the notion that the stock may be undervalued relative to its potential...."
      },
      {
        "title": "CareDx, Inc. Experiences Revision in Stock Evaluation Amid Challenging Financial Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/caredx-inc-sees-valuation-grade-upgrade-from-attractive-to-very-attractive-3619710",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CareDxInc_valuationdot_3619710.png",
        "date": "2025-10-14 15:36:02",
        "description": "CareDx, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, is facing financial challenges, evidenced by its negative P/E ratio and low ROCE and ROE. The company's stock performance has been volatile, with a year-to-date return significantly lower than the S&P 500, highlighting a competitive landscape."
      },
      {
        "title": "Is CareDx, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-caredx-inc-overvalued-or-undervalued-3612681",
        "imagepath": "",
        "date": "2025-10-12 11:08:28",
        "description": "As of 10 October 2025, the valuation grade for CareDx, Inc. has moved from attractive to very attractive, indicating a positive shift in its valuation outlook. Despite this upgrade, the company appears to be overvalued based on its current financial metrics. The Price to Book Value stands at 2.87, while the EV to Sales ratio is 2.49, both suggesting that the stock may be priced higher than its fundamental value. Additionally, the EV to EBIT ratio is notably negative at -27.94, reflecting ongoing losses.\n\nIn comparison to its peers, CareDx, Inc. has a similar EV to EBITDA ratio of -27.82, which highlights the challenges faced by the company relative to its industry. Notably, while CareDx has experienced a 1-month return of 7.95%, it has significantly underperformed against the S&P 500, which returned 0.31% during the same period. Over the past year, CareDx's stock has declined by 52.87%, contrasting sharply ..."
      },
      {
        "title": "CareDx, Inc. Experiences Revision in Stock Evaluation Amidst Challenging Market Conditions",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/caredx-inc-sees-valuation-grade-downgrade-from-very-attractive-to-attractive-3552780",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/CareDxInc_valuationdot_3552780.png",
        "date": "2025-09-22 18:17:52",
        "description": "CareDx, Inc. has experienced a valuation adjustment amid operational challenges, reflected in its financial metrics. The company reports a Price to Book Value of 2.87 and significant declines in stock performance, with a year-to-date drop of 31.85%. Comparatively, its peers show stronger valuation metrics and operational efficiency."
      },
      {
        "title": "Is CareDx, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-caredx-inc-technically-bullish-or-bearish-3546193",
        "imagepath": "",
        "date": "2025-09-20 19:26:49",
        "description": "As of 2 September 2025, the technical trend for CareDx, Inc. has changed from mildly bearish to bearish. The overall stance is bearish with weak strength indicated by the MACD being bearish on a monthly basis and the KST also showing bearish signals. While the weekly MACD and RSI are mildly bullish and bullish respectively, the moving averages and Bollinger Bands indicate a mildly bearish trend on both weekly and monthly timeframes. Additionally, the Dow Theory shows a mildly bullish signal on the weekly but is bearish on the monthly. \n\nIn terms of performance, CareDx has underperformed against the S&P 500 over the year and longer periods, with a 1-year return of -49.52% compared to the S&P 500's 17.14%...."
      },
      {
        "title": "Is CareDx, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-caredx-inc-overvalued-or-undervalued-3542810",
        "imagepath": "",
        "date": "2025-09-20 18:02:48",
        "description": "As of 7 July 2025, CareDx, Inc. has moved from a fair to a very attractive valuation grade. The company appears to be undervalued, particularly given its current price of 14.77, which is significantly lower than its 52-week high of 32.97. Key valuation ratios include a Price to Book Value of 2.87, an EV to Sales ratio of 2.49, and an EV to Capital Employed ratio of 5.58, which suggest potential for growth despite the company's current losses.\n\nIn comparison to peers, CareDx's EV to EBITDA ratio stands at -27.94, while Organogenesis Holdings, Inc. has a P/E ratio of 608.59, indicating a stark contrast in valuation metrics. Similarly, Castle Biosciences, Inc. shows an EV to EBITDA of -71.36, further highlighting CareDx's relative positioning in the market. Notably, while CareDx has experienced a 49.52% decline over the past year, the S&P 500 has returned 17.14%, reinforcing the notion that CareDx may be under..."
      }
    ],
    "total": 13,
    "sid": "1151878",
    "stock_news_url": "https://www.marketsmojo.com/news/caredx-inc-1151878"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is CareDx, Inc. overvalued or undervalued?

2025-10-21 12:06:21

As of 17 October 2025, the valuation grade for CareDx, Inc. has moved from fair to very attractive, indicating a significant improvement in its perceived value. Based on the available metrics, CareDx appears to be undervalued, especially considering its Price to Book Value of 2.87 and an EV to Capital Employed ratio of 5.58, despite its negative earnings metrics. The company’s EV to Sales ratio stands at 2.49, which suggests a reasonable valuation relative to its sales, particularly when compared to peers like Organogenesis Holdings, Inc. with a P/E of 608.59 and Castle Biosciences, Inc. with an EV to EBITDA of -71.36. In terms of stock performance, CareDx has faced substantial declines, with a year-to-date return of -32.70% compared to the S&P 500's 13.30%, and a five-year return of -72.05% against the S&P 500's 91.29%. This stark contrast reinforces the notion that CareDx may be undervalued, as its curre...

Is CareDx, Inc. overvalued or undervalued?

2025-10-20 12:23:41

As of 17 October 2025, the valuation grade for CareDx, Inc. moved from fair to very attractive, indicating a significant improvement in its valuation outlook. The company appears undervalued, particularly given its Price to Book Value of 2.87 and an EV to Sales ratio of 2.49, despite the negative P/E and ROE figures. CareDx's EV to EBIT stands at -27.94, which reflects its current loss-making status but also highlights potential for future recovery. In comparison to its peers, CareDx's valuation metrics are notably more favorable, especially when contrasted with Organogenesis Holdings, Inc., which has a P/E ratio of 608.59, and Castle Biosciences, Inc., with an EV to EBITDA of -71.36. While CareDx has not provided multi-period return data, the overall market sentiment indicates a potential upside as it continues to navigate its challenges....

Is CareDx, Inc. overvalued or undervalued?

2025-10-19 12:01:14

As of 17 October 2025, CareDx, Inc. moved from fair to very attractive in valuation grade. The company appears undervalued given its current Price to Book Value of 2.87 and an EV to Capital Employed ratio of 5.58, despite being loss-making and having negative returns on capital and equity. In comparison to peers, CareDx's EV to EBITDA stands at -27.94, while Organogenesis Holdings, Inc. has a significantly higher P/E ratio of 608.59, indicating a stark contrast in valuation. Notably, CareDx's stock has underperformed against the S&P 500, with a year-to-date return of -32.70% compared to the index's 13.30%. This trend continues over longer periods, with a 5-year return of -72.05% versus the S&P 500's 91.29%, reinforcing the notion that the stock may be undervalued relative to its potential....

CareDx, Inc. Experiences Revision in Stock Evaluation Amid Challenging Financial Metrics

2025-10-14 15:36:02

CareDx, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, is facing financial challenges, evidenced by its negative P/E ratio and low ROCE and ROE. The company's stock performance has been volatile, with a year-to-date return significantly lower than the S&P 500, highlighting a competitive landscape.

Is CareDx, Inc. overvalued or undervalued?

2025-10-12 11:08:28

As of 10 October 2025, the valuation grade for CareDx, Inc. has moved from attractive to very attractive, indicating a positive shift in its valuation outlook. Despite this upgrade, the company appears to be overvalued based on its current financial metrics. The Price to Book Value stands at 2.87, while the EV to Sales ratio is 2.49, both suggesting that the stock may be priced higher than its fundamental value. Additionally, the EV to EBIT ratio is notably negative at -27.94, reflecting ongoing losses. In comparison to its peers, CareDx, Inc. has a similar EV to EBITDA ratio of -27.82, which highlights the challenges faced by the company relative to its industry. Notably, while CareDx has experienced a 1-month return of 7.95%, it has significantly underperformed against the S&P 500, which returned 0.31% during the same period. Over the past year, CareDx's stock has declined by 52.87%, contrasting sharply ...

CareDx, Inc. Experiences Revision in Stock Evaluation Amidst Challenging Market Conditions

2025-09-22 18:17:52

CareDx, Inc. has experienced a valuation adjustment amid operational challenges, reflected in its financial metrics. The company reports a Price to Book Value of 2.87 and significant declines in stock performance, with a year-to-date drop of 31.85%. Comparatively, its peers show stronger valuation metrics and operational efficiency.

Is CareDx, Inc. technically bullish or bearish?

2025-09-20 19:26:49

As of 2 September 2025, the technical trend for CareDx, Inc. has changed from mildly bearish to bearish. The overall stance is bearish with weak strength indicated by the MACD being bearish on a monthly basis and the KST also showing bearish signals. While the weekly MACD and RSI are mildly bullish and bullish respectively, the moving averages and Bollinger Bands indicate a mildly bearish trend on both weekly and monthly timeframes. Additionally, the Dow Theory shows a mildly bullish signal on the weekly but is bearish on the monthly. In terms of performance, CareDx has underperformed against the S&P 500 over the year and longer periods, with a 1-year return of -49.52% compared to the S&P 500's 17.14%....

Is CareDx, Inc. overvalued or undervalued?

2025-09-20 18:02:48

As of 7 July 2025, CareDx, Inc. has moved from a fair to a very attractive valuation grade. The company appears to be undervalued, particularly given its current price of 14.77, which is significantly lower than its 52-week high of 32.97. Key valuation ratios include a Price to Book Value of 2.87, an EV to Sales ratio of 2.49, and an EV to Capital Employed ratio of 5.58, which suggest potential for growth despite the company's current losses. In comparison to peers, CareDx's EV to EBITDA ratio stands at -27.94, while Organogenesis Holdings, Inc. has a P/E ratio of 608.59, indicating a stark contrast in valuation metrics. Similarly, Castle Biosciences, Inc. shows an EV to EBITDA of -71.36, further highlighting CareDx's relative positioning in the market. Notably, while CareDx has experienced a 49.52% decline over the past year, the S&P 500 has returned 17.14%, reinforcing the notion that CareDx may be under...

View All News